The Experts below are selected from a list of 9171 Experts worldwide ranked by ideXlab platform
Eric B Rimm - One of the best experts on this subject based on the ideXlab platform.
-
Calcium Supplement intake and risk of cardiovascular disease in women
Osteoporosis International, 2014Co-Authors: Julie M Paik, Gary C Curhan, Kathryn M Rexrode, Joann E Manson, Eric B RimmAbstract:Summary Some recent reports suggest that Calcium Supplement use may increase risk of cardiovascular disease. In a prospective cohort study of 74,245 women in the Nurses' Health Study with 24 years of follow-up, we found no independent associations between Supplemental Calcium intake and risk of incident coronary heart disease (CHD) and stroke.
Dennis B. Denicola - One of the best experts on this subject based on the ideXlab platform.
-
Blood Smear from a Wild-Caught Panther
2015Co-Authors: O R. Irizarry-rovira, Matthew G. Bolek, John A. Christian, Er Wolf, Dennis B. DenicolaAbstract:A wild-caught male panther chameleon (Furcifer pardalis, previously known as Chamaleo pardalis) import-ed from Madagascar and of unknown age was present-ed to the Avian and Exotic Animal Clinic of Lafayette with a complaint of anorexia.The chameleon’s diet con-sisted primarily of crickets, which the owner occasional-ly would dust with Calcium Supplement. Although phys-ically vigorous, the patient was thin (52 g), exhibited poor coloration (Figure 1A), and had pale oral mucous membranes. Physical examination revealed 4 multifocal, poorly defined small bulges underneath the skin (not shown). Two of the bulges were located behind the left forearm, and the other 2 were located cranial to the right rear limb. As part of the diagnostic workup, heparinized blood samples were collected and used to prepare sev-eral air-dried smears and wet preparations. Most blood smears were stained with a rapid Romanowsky stai
-
Blood smear from a wild-caught panther chameleon (Furcifer pardalis).
Veterinary Clinical Pathology, 2002Co-Authors: Armando R. Irizarry-rovira, Alexander Wolf, Matthew G. Bolek, John A. Christian, Dennis B. DenicolaAbstract:Case Presentation A wild-caught male panther chameleon (Furcifer pardalis, previously known as Chamaleo pardalis) imported from Madagascar and of unknown age was presented to the Avian and Exotic Animal Clinic of Lafayette with a complaint of anorexia. The chameleon’s diet consisted primarily of crickets, which the owner occasionally would dust with Calcium Supplement. Although physically vigorous, the patient was thin (52 g), exhibited poor coloration (Figure 1A), and had pale oral mucous membranes. Physical examination revealed 4 multifocal, poorly defined small bulges underneath the skin (not shown). Two of the bulges were located behind the left forearm, and the other 2 were located cranial to the right rear limb. As part of the diagnostic workup, heparinized blood samples were collected and used to prepare several air-dried smears and wet preparations. Most blood smears were stained with a rapid Romanowsky stain (Diff-Quik, Dade Diagnostics, Aguada, Puerto Rico).The remaining blood smears were later stained with an automated Romanowsky stain (Hematek, Bayer Diagnostics, Elkhart, Ind) at the Purdue University Veterinary Clinical Pathology Laboratory (Figure 1B). Other laboratory tests (clinical chemistry, PCV, CBC) were not done because of the limited amount of blood available. (Continued on next page)
-
Blood smear from a wild-caught panther chameleon (Furcifer pardalis).
Veterinary Clinical Pathology, 2002Co-Authors: Armando R. Irizarry-rovira, Alexander Wolf, Matthew G. Bolek, John A. Christian, Dennis B. DenicolaAbstract:Case Presentation A wild-caught male panther chameleon (Furcifer pardalis, previously known as Chamaleo pardalis) imported from Madagascar and of unknown age was presented to the Avian and Exotic Animal Clinic of Lafayette with a complaint of anorexia. The chameleon’s diet consisted primarily of crickets, which the owner occasionally would dust with Calcium Supplement. Although physically vigorous, the patient was thin (52 g), exhibited poor coloration (Figure 1A), and had pale oral mucous membranes. Physical examination revealed 4 multifocal, poorly defined small bulges underneath the skin (not shown). Two of the bulges were located behind the left forearm, and the other 2 were located cranial to the right rear limb. As part of the diagnostic workup, heparinized blood samples were collected and used to prepare several air-dried smears and wet preparations. Most blood smears were stained with a rapid Romanowsky stain (Diff-Quik, Dade Diagnostics, Aguada, Puerto Rico).The remaining blood smears were later stained with an automated Romanowsky stain (Hematek, Bayer Diagnostics, Elkhart, Ind) at the Purdue University Veterinary Clinical Pathology Laboratory (Figure 1B). Other laboratory tests (clinical chemistry, PCV, CBC) were not done because of the limited amount of blood available. (Continued on next page)
Hong Yuan - One of the best experts on this subject based on the ideXlab platform.
-
water ph dual responsive in situ Calcium Supplement collaborates simvastatin for osteoblast promotion mediated osteoporosis therapy via oral medication
Journal of Controlled Release, 2021Co-Authors: Shan Tao, Yanqing Song, Wentao Zhou, Rui Zhao, Cheng Wang, Hong YuanAbstract:Abstract Calcium Supplement is the most commonly adopted treatment for osteoporosis but usually requires high dose and frequency. The modality of Calcium Supplement is therefore overlooked by current nanomedicine-based osteoporosis therapies without proper oral formulations. Herein, we proposed a tetracycline (Tc) modified and monostearin (MS) coated amorphous Calcium carbonate (ACC) platform (TMA) as oral bone targeted and osteoporosis microenvironment (water/pH) responsive carrier for in situ Calcium Supplement. Moreover, current osteoporosis therapies also fall short of finding suitable molecular target and effective therapeutic regimen to further increase the therapeutic efficacy over available treatment means. As a result, the simvastatin (Sim) was loaded into TMA to construct drug delivery system (TMA/Sim) capable of synergistically activating the bone morphogenetic proteins (BMPs)-Smad pathway to provide a novel therapeutic regimen for osteoblast promotion mediated osteoporosis therapy. Our results revealed that optimized TMA showed high accessibility and oral availability with targeted drug delivery to bone tissue. Most importantly, benefit from the effective in situ Calcium Supplement and targeted Sim delivery, this therapeutic regime (TMA/Sim) achieved better synergetic effects than conventional combination strategies with promising osteoporosis reversion performance under low Calcium dosage (1/10 of commercial Calcium carbonate tablet) and significantly attenuated side effects.
-
Calcium Supplement by tetracycline guided amorphous Calcium carbonate potentiates osteoblast promotion for synergetic osteoporosis therapy
Theranostics, 2020Co-Authors: Jianwei Wang, Shan Tao, Xiangyu Jin, Yanqing Song, Wentao Zhou, Haiya Lou, Rui Zhao, Cheng Wang, Hong YuanAbstract:Background: The Calcium Supplement is a clinically approved approach for osteoporosis therapy but usually requires a large dosage without targetability and with poor outcome. This modality is not fully explored in current osteoporosis therapy due to the lack of proper Calcium Supplement carrier. Methods: In this study, we constructed a tetracycline (Tc) modified and simvastatin (Sim) loaded phospholipid-amorphous Calcium carbonate (ACC) hybrid nanoparticle (Tc/ACC/Sim). Results: The resulted Tc/ACC/Sim was able to enhance its accumulation at the osteoporosis site. Most importantly, the combination of Calcium Supplement and Sim offered synergetic osteoblast promotion therapy of osteoporosis with advanced performance than non-targeted system or mono therapy. Conclusion: This platform provides an alternative approach to stimulate bone formation by synergetic promotion of osteoblast differentiation using Calcium Supplement and Sim.
S. Neupane - One of the best experts on this subject based on the ideXlab platform.
-
incidence of milk alkali syndrome in the women s health initiative clinical trial and cohort study
Osteoporosis International, 2014Co-Authors: S. NeupaneAbstract:Dear Editor, Milk alkali syndrome is a condition which has been considered to be on the rise with the use of Calcium carbonate for osteoporosis prevention globally. It is considered to be the third most common cause of hypercalcemia in non-end-stage renal disease inpatients [1, 2]. There have been many reports of milk alkali syndrome from Calcium carbonate intake ranging from 1 to 9 g of elemental Calcium per day. However, most of these patients had other comorbidities like chronic kidney disease or use of diuretics, which can predispose them to the syndrome [1]. In the article “Health risks and benefits from Calcium and vitamin D Supplementation: Women’s Health Initiative clinical trial and cohort study” [3], Dr. Prentice and colleagues addressed the health benefits and risks seen with Calcium and vitamin D Supplementation, but they have not mentioned anything about the occurrence or absence of milk alkali syndrome in this large sample. The study included a significant number of subjects who were more than 70 years of age and significant number of subjects who were taking more than 1,200 mg/day of Calcium in the form of Calcium carbonate along with vitamin D Supplementation. Increasing reports of milk alkali syndrome with Calcium carbonate use raises the question if just Calcium citrate should be used for osteoporosis prevention despite the higher cost of administering Calcium citrate compared to administering Calcium carbonate. It will help clinicians make a choice regarding the type of Calcium Supplement if the authors could clarify if there was any occurrence of milk alkali syndrome in the large sample from the community that was followed up for 7 years. Additional information about the prevalence of chronic kidney disease, use of diuretics, and use of proton pump inhibitors in those patients will also help in the decision making.
-
Incidence of milk alkali syndrome in the Women’s Health Initiative clinical trial and cohort study
Osteoporosis International, 2013Co-Authors: S. NeupaneAbstract:Dear Editor, Milk alkali syndrome is a condition which has been considered to be on the rise with the use of Calcium carbonate for osteoporosis prevention globally. It is considered to be the third most common cause of hypercalcemia in non-end-stage renal disease inpatients [1, 2]. There have been many reports of milk alkali syndrome from Calcium carbonate intake ranging from 1 to 9 g of elemental Calcium per day. However, most of these patients had other comorbidities like chronic kidney disease or use of diuretics, which can predispose them to the syndrome [1]. In the article “Health risks and benefits from Calcium and vitamin D Supplementation: Women’s Health Initiative clinical trial and cohort study” [3], Dr. Prentice and colleagues addressed the health benefits and risks seen with Calcium and vitamin D Supplementation, but they have not mentioned anything about the occurrence or absence of milk alkali syndrome in this large sample. The study included a significant number of subjects who were more than 70 years of age and significant number of subjects who were taking more than 1,200 mg/day of Calcium in the form of Calcium carbonate along with vitamin D Supplementation. Increasing reports of milk alkali syndrome with Calcium carbonate use raises the question if just Calcium citrate should be used for osteoporosis prevention despite the higher cost of administering Calcium citrate compared to administering Calcium carbonate. It will help clinicians make a choice regarding the type of Calcium Supplement if the authors could clarify if there was any occurrence of milk alkali syndrome in the large sample from the community that was followed up for 7 years. Additional information about the prevalence of chronic kidney disease, use of diuretics, and use of proton pump inhibitors in those patients will also help in the decision making.
Joann E Manson - One of the best experts on this subject based on the ideXlab platform.
-
Calcium Supplement intake and risk of cardiovascular disease in women
Osteoporosis International, 2014Co-Authors: Julie M Paik, Gary C Curhan, Kathryn M Rexrode, Joann E Manson, Eric B RimmAbstract:Summary Some recent reports suggest that Calcium Supplement use may increase risk of cardiovascular disease. In a prospective cohort study of 74,245 women in the Nurses' Health Study with 24 years of follow-up, we found no independent associations between Supplemental Calcium intake and risk of incident coronary heart disease (CHD) and stroke.
-
Calcium Intake and Risk of Cardiovascular Disease
American Journal of Cardiovascular Drugs, 2012Co-Authors: Lu Wang, Joann E Manson, Howard D. SessoAbstract:The potential effects of inadequate or excessive Calcium supply on cardiovascular disease (CVD) are receiving growing attention. We review experimental, epidemiologic, and clinical evidence regarding the role of Calcium intake in the development of CVD in adults. In vitro and in vivo laboratory studies have shown that Calcium may affect the risk of developing CVD through multiple mechanisms including blood cholesterol, insulin secretion and sensitivity, vasodilation, inflammatory profile, thrombosis, obesity, and vascular calcification. A number of prospective epidemiologic studies have examined the relationship between dietary Calcium intake and CVD incidence or mortality in middle-aged and older adults. The results were inconsistent, and the pooled data do not strongly support a significant effect of greater dietary Calcium intake on the risk of coronary artery disease (CAD) or stroke. Only a few prospective studies have examined Calcium Supplement use in association with risk of CVD. The pooled data show no significant benefits of Calcium Supplement use in reducing the risk of CAD or stroke. No randomized clinical trial has specifically tested the effect of Calcium Supplementation on CVD as its primary endpoint. Secondary analyses in existing trials to date suggest a neutral effect of Calcium (with or without vitamin D) Supplements on CVD events, but do not allow for a definitive conclusion. A large percentage of Americans, particularly older adults, fail to meet the US recommendations for optimal Calcium intake and are encouraged to increase daily Calcium consumption. More prospective cohort studies and large-scale randomized trials are needed to further evaluate the risks or benefits of Calcium Supplementation on CVD endpoints as the primary pre-specified outcome.
